이 기사의 번역을 준비하고 있습니다. 그동안 영어 원문을 임시로 표시합니다.
규제 및 법률 · 2019. 10. 3.1 분 읽기
Prospective Grant of an Exclusive Patent License: Compositions, Devices and Processes for Production and Delivery of Cell Grafts of Manufactured Retinal Pigment Epithelium Cell(s) Alone, or in Combination With Photoreceptor Cells, and on a Biodegradable Support Scaffold Transplanted Subretinally for Intra-Ocular Ophthalmic Treatment of Conditions of Degeneration, Dysfunction or Terminal Injury of Retinal Pigment Epithelium and/or Photoreceptors in Humans
로컬 자동 번역 · 원본 출처 언어
요약
The National Eye Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Opsis Therapeutics, LLC, ("Opsis") located in Madison Wisconsin and its affiliate, FUJIFILM Cellular Dynamics, Inc.
원본 출처 언어: Federal Register — All Documents원문 발표 열기 →